MCID: MCR115
MIFTS: 66

Microvascular Complications of Diabetes 5

Categories: Genetic diseases, Eye diseases, Neuronal diseases, Nephrological diseases

Aliases & Classifications for Microvascular Complications of Diabetes 5

MalaCards integrated aliases for Microvascular Complications of Diabetes 5:

Name: Microvascular Complications of Diabetes 5 53 71 28 13 37
Diabetic Retinopathy 37 12 36 28 51 41 14 69
Retinopathy, Diabetic 53 72
Diabetic Nephropathy 71 69
Mvcd5 53 71
Microvascular Complications of Diabetes, Susceptibility to, 5 53
Retinopathy, Diabetic, Susceptibility to 53
Retinal Abnormality - Diabetes-Related 12

Classifications:



External Ids:

OMIM 53 612633
Disease Ontology 12 DOID:8947
ICD9CM 34 362.0
NCIt 46 C34538
MedGen 39 C2674665
KEGG 36 H01457
ICD10 32 H36.0

Summaries for Microvascular Complications of Diabetes 5

UniProtKB/Swiss-Prot : 71 Microvascular complications of diabetes 5: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary : Microvascular Complications of Diabetes 5, also known as diabetic retinopathy, is related to severe nonproliferative diabetic retinopathy and background diabetic retinopathy. An important gene associated with Microvascular Complications of Diabetes 5 is PON1 (Paraoxonase 1), and among its related pathways/superpathways are AGE-RAGE signaling pathway in diabetic complications and HIF-1 signaling pathway. The drugs Bevacizumab and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include Eye and Eye, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 72 Diabetic retinopathy, also known as diabetic eye disease, is a medical condition in which damage occurs... more...

Description from OMIM: 612633

Related Diseases for Microvascular Complications of Diabetes 5

Diseases in the Microvascular Complications of Diabetes 5 family:

Microvascular Complications of Diabetes 1 Microvascular Complications of Diabetes 2
Microvascular Complications of Diabetes 3 Microvascular Complications of Diabetes 4
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 5 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 111)
# Related Disease Score Top Affiliating Genes
1 severe nonproliferative diabetic retinopathy 34.1 INS VEGFA
2 background diabetic retinopathy 33.9 ALB ANGPT2 INS VEGFA
3 microvascular complications of diabetes 1 32.1 ANGPT2 FGF2 FLT1 ICAM1 IGF1 SERPINF1
4 microvascular complications of diabetes 3 31.5 ACE AGER AKR1B1 ALB INS
5 macular retinal edema 29.9 ICAM1 PRKCB SERPINF1 VEGFA
6 macular degeneration, age-related, 1 29.4 FGF2 FLT1 KDR SERPINF1 VEGFA
7 diabetes mellitus 28.7 ACE AKR1B1 ALB AOC3 IGF1 INS
8 diabetic macular edema 28.6 FGF2 ICAM1 NOS3 PRKCB SERPINF1 TEK
9 microvascular complications of diabetes 2 11.9
10 microvascular complications of diabetes 7 11.8
11 microvascular complications of diabetes 4 10.9
12 microvascular complications of diabetes 6 10.9
13 retinitis pigmentosa-intellectual disability-deafness-hypogonadism syndrome 10.9
14 diabetic cataract 10.5 AKR1B1 SERPINF1 VEGFA
15 hypertensive nephropathy 10.5 ACE ALB VEGFA
16 lymphangioma 10.4 KDR SERPINF1 VEGFA
17 autonomic neuropathy 10.4 AKR1B1 ALB INS
18 secondary adrenal insufficiency 10.4 IGF1 INS
19 severe pre-eclampsia 10.4 ALB VCAM1 VEGFA
20 skin sarcoidosis 10.4 ACE SERPINF1
21 angiokeratoma circumscriptum 10.4 FLT1 KDR VEGFA
22 vascular dementia 10.4 ACE PON1 VEGFA
23 ovarian hyperstimulation syndrome 10.4 ALB KDR VEGFA
24 hemifacial spasm 10.4 NOS3 VEGFA
25 macular holes 10.4 ANGPT2 SERPINF1 VEGFA
26 epithelioid hemangioendothelioma 10.4 FLT1 KDR VEGFA
27 rubeosis iridis 10.4 IGF1 INS VEGFA
28 acute hemorrhagic leukoencephalitis 10.4 FLT1 KDR VEGFA
29 lipodermatosclerosis 10.4 ANGPT2 FLT1 VEGFA
30 diabetic polyneuropathy 10.4 AGER AKR1B1 VEGFA
31 hepatopulmonary syndrome 10.4 ALB NOS3 VEGFA
32 urinary system disease 10.4 ACE ALB INS
33 diabetic neuropathy 10.4 ACE AKR1B1 INS VEGFA
34 lutheran suppressor, x-linked 10.4 INS PON1 SERPINE1
35 radiation proctitis 10.3 FGF2 KDR VEGFA
36 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.3 IGF1 INS
37 respiratory system disease 10.3 ACE ALB ICAM1
38 portal hypertension 10.3 ALB NOS3 VEGFA
39 trypanosomiasis 10.3 ALB ICAM1 VCAM1
40 angiomatous meningioma 10.3 FGF2 KDR VEGFA
41 lymphocytic vasculitis 10.3 ICAM1 VCAM1
42 retinal vein occlusion 10.3 SERPINE1 SERPINF1 VEGFA
43 leukostasis 10.3 ICAM1 KDR VCAM1 VEGFA
44 familial hyperlipidemia 10.3 INS PON1 SERPINE1
45 pulmonary edema 10.3 ACE ICAM1 NOS3
46 subendocardial myocardial infarction 10.3 ICAM1 SERPINE1 VCAM1
47 shwartzman phenomenon 10.3 ICAM1 SERPINE1 VCAM1
48 critical limb ischemia 10.3 ANGPT2 TEK VEGFA
49 peripheral artery disease 10.3 ACE NOS3 VCAM1 VEGFA
50 pyogenic granuloma 10.3 ANGPT2 TEK VEGFA

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 5:



Diseases related to Microvascular Complications of Diabetes 5

Symptoms & Phenotypes for Microvascular Complications of Diabetes 5

Clinical features from OMIM:

612633

MGI Mouse Phenotypes related to Microvascular Complications of Diabetes 5:

43 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.5 IGF1 FGF2 KDR FLT1 ACE INS
2 homeostasis/metabolism MP:0005376 10.48 IGF1 FGF2 FLT1 AKR1B1 ALB ACE
3 hematopoietic system MP:0005397 10.44 IGF1 FGF2 FLT1 ACE INS ICAM1
4 cellular MP:0005384 10.4 AOC3 IGF1 FGF2 FLT1 ALB INS
5 immune system MP:0005387 10.39 IGF1 FLT1 ACE INS ICAM1 ANGPT2
6 growth/size/body region MP:0005378 10.36 AGER IGF1 AKR1B1 FLT1 ACE INS
7 mortality/aging MP:0010768 10.33 IGF1 FGF2 AKR1B1 FLT1 ALB ACE
8 muscle MP:0005369 10.17 IGF1 FGF2 FLT1 ALB INS ICAM1
9 nervous system MP:0003631 10.11 FGF2 IGF1 FLT1 ICAM1 INS NOS3
10 integument MP:0010771 10.1 INS AGER IGF1 ANGPT2 ICAM1 KDR
11 liver/biliary system MP:0005370 10.02 INS ALB ACE NOS3 KDR SERPINE1
12 normal MP:0002873 9.97 AGER IGF1 FLT1 ALB INS KDR
13 neoplasm MP:0002006 9.95 FGF2 IGF1 ALB ACE ICAM1 SERPINE1
14 renal/urinary system MP:0005367 9.91 AGER IGF1 AKR1B1 ALB ACE INS
15 reproductive system MP:0005389 9.81 FGF2 IGF1 FLT1 ACE INS SERPINF1
16 skeleton MP:0005390 9.61 AGER AKR1B1 FGF2 IGF1 INS NOS3
17 vision/eye MP:0005391 9.36 FGF2 AKR1B1 FLT1 INS ICAM1 ANGPT2

Drugs & Therapeutics for Microvascular Complications of Diabetes 5

Drugs for Microvascular Complications of Diabetes 5 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 384)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 216974-75-3
2
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 347396-82-1 459903
3
Acarbose Approved, Investigational Phase 4,Early Phase 1 56180-94-0 441184
4
Pioglitazone Approved, Investigational Phase 4,Not Applicable 111025-46-8 4829
5
Hydroxocobalamin Approved Phase 4,Not Applicable 13422-51-0 5460373 44475014 11953898
6
Glatiramer Acetate Approved, Investigational Phase 4 147245-92-9 3081884
7
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
8
Fenofibrate Approved Phase 4,Phase 3 49562-28-9 3339
9
Verteporfin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129497-78-5
10
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
11
Nitric Oxide Approved Phase 4 10102-43-9 145068
12
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 50-02-2 5743
13
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-66-6 32051 23994
14
Povidone-iodine Approved Phase 4,Phase 3,Not Applicable 25655-41-8
15
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 124-94-7 31307
16
Temazepam Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 846-50-4 5391
17
Nepafenac Approved, Investigational Phase 4,Phase 3,Phase 2 78281-72-8 151075
18
Eplerenone Approved Phase 4,Phase 2,Phase 3 107724-20-9 443872 150310
19
Spironolactone Approved Phase 4,Phase 2,Phase 3 1952-01-7, 52-01-7 5833
20
Latanoprost Approved, Investigational Phase 4,Not Applicable 130209-82-4 5311221 5282380
21
Dipivefrin Approved Phase 4,Not Applicable 52365-63-6 3105
22
Insulin Glargine Approved Phase 4,Early Phase 1 160337-95-1
23
Lidocaine Approved, Vet_approved Phase 4,Phase 3 137-58-6 3676
24
Menthol Approved Phase 4,Not Applicable 2216-51-5 16666
25
Betamethasone Approved, Vet_approved Phase 4,Phase 1 378-44-9 9782
26 Homatropine Approved Phase 4 87-00-3
27
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
28
Copper Approved, Investigational Phase 4,Phase 2 7440-50-8 27099
29
Nitroglycerin Approved, Investigational Phase 4,Not Applicable 55-63-0 4510
30
Lisinopril Approved, Investigational Phase 4,Not Applicable 83915-83-7, 76547-98-3 5362119
31
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
32
Amlodipine Approved Phase 4,Not Applicable 88150-42-9 2162
33
Empagliflozin Approved Phase 4,Phase 3 864070-44-0
34
Glimepiride Approved Phase 4 93479-97-1 3476
35
Bisoprolol Approved Phase 4 66722-44-9 2405
36
Captopril Approved Phase 4 62571-86-2 44093
37
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
38
Cilazapril Approved Phase 4 88768-40-5, 92077-78-6 56330 56329
39
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5362032
40
Enalaprilat Approved Phase 4 76420-72-9 6917719
41
Eprosartan Approved Phase 4 133040-01-4 5281037
42
Fosinopril Approved Phase 4 98048-97-6 55891
43
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
44
Losartan Approved Phase 4 114798-26-4 3961
45
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
46
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
47
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
48
Ramipril Approved Phase 4 87333-19-5 5362129
49
Spirapril Approved Phase 4 83647-97-6 5311447
50
Trandolapril Approved Phase 4 87679-37-6 5484727

Interventional clinical trials:

(show top 50) (show all 733)

# Name Status NCT ID Phase Drugs
1 Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED) Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
2 PASCAL Laser Versus ETDRS Laser Associated With Intravitreal Ranibizumab (IVR) Versus Only IVR for Proliferative Diabetic Retinopathy Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
3 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
4 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
5 Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy Unknown status NCT01382498 Phase 4 Calcium dobesilate (Doxium);Placebo drug
6 Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
7 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
8 Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation Unknown status NCT00677664 Phase 4 Glatiramer acetate (Copaxone);Mannitol
9 Effects of Fenofibrate on Endothelial Progenitor Cells in Diabetes Unknown status NCT01927315 Phase 4 Fenofibrate 145 mg;Placebo
10 Ranibizumab in Diabetic Vitrectomy Unknown status NCT01306981 Phase 4 Ranibizumab;Saline
11 Changes in Macular Thickness After Patterns Scan Laser Unknown status NCT00563628 Phase 4
12 Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO) Unknown status NCT02432547 Phase 4 Aflibercept
13 Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment Unknown status NCT00563043 Phase 4
14 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
15 Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration Unknown status NCT00813891 Phase 4 Ranibizumab;Ranibizumab;Ranibizumab
16 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
17 Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration. Unknown status NCT01918878 Phase 4 Aflibercept (EYLEA)
18 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
19 Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema Unknown status NCT02633852 Phase 4 Aflibercept
20 Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema Unknown status NCT02684084 Phase 4 Ozurdex;Lucentis
21 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
22 The Endurance 1 Trial Unknown status NCT02297204 Phase 4 aflibercept 2.0 mg
23 On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD) Unknown status NCT01670162 Phase 4 Aflibercept
24 Topical Application of Latanoprost in Diabetic Retinopathy Completed NCT01225653 Phase 4 Latanoprost
25 Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy Completed NCT01724385 Phase 4 intravitreal injection of bevacizumab
26 Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT01025934 Phase 4 Bevacizumab
27 Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE) Completed NCT01594281 Phase 4 Ranibizumab
28 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
29 Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients Completed NCT00174824 Phase 4 Insulin glargine
30 Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
31 Effect of the Adjunctive IVB Before PRP Completed NCT01504724 Phase 4 bevacizumab
32 Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation Completed NCT01223612 Phase 4 Ranibizumab
33 Unilateral Bevacizumab for Bilateral Diabetic Macular Edema Completed NCT00496405 Phase 4 bevacizumab
34 Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema Completed NCT02366468 Phase 4 0.5 mg ranibizumab;0.5 mg ranibizumab
35 Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment Completed NCT01257815 Phase 4 Ranibizumab
36 Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma Completed NCT02647515 Phase 4 ranibizumab
37 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Completed NCT00682240 Phase 4
38 Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema Completed NCT00682539 Phase 4 Bevacizumab (Avastin);Triamcinolone;Sham
39 PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs Completed NCT02249897 Phase 4 CHOLESTYRAMINE
40 Parameters of 2 Phaco Tips Designs in Torsional Phacoemulsification Completed NCT02089698 Phase 4
41 Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection) Completed NCT01722045 Phase 4 Intravitreal Aflibercept Injection (IAI)
42 TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4 Ozurdex Intravitreal Injection (0.7 mg)
43 Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions Completed NCT00324116 Phase 4 pegaptanib sodium (Macugen)
44 Avastin for Post-Photocoagulation Macular Edema Completed NCT00801866 Phase 4 Bevacizumab
45 Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema. Completed NCT00758628 Phase 4 Bromefenac;Blink
46 Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema Completed NCT01309451 Phase 4 Bevacizumab;dexamethasone intravitreal implant
47 20- Versus 23- Gauge System for Pars Plana Vitrectomy Completed NCT00411970 Phase 4
48 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema Completed NCT01546402 Phase 4 Dexamethasone Drug delivery system (Ozurdex)
49 Effect of Antioxidants on Ocular Blood Flow, Endothelial Function, and Cytokine Levels in LPS Induced Inflammatory Model in Humans. Completed NCT00431691 Phase 4 vitamin and mineral supplement;Escherichia coli Endotoxin (LPS);100% O2;nitroglycerin
50 Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Completed NCT01310127 Phase 4 Bromfenac;Nepafenac

Search NIH Clinical Center for Microvascular Complications of Diabetes 5

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cochrane evidence based reviews: diabetic retinopathy

Genetic Tests for Microvascular Complications of Diabetes 5

Genetic tests related to Microvascular Complications of Diabetes 5:

# Genetic test Affiliating Genes
1 Diabetic Retinopathy 28
2 Microvascular Complications of Diabetes 5 28 PON1

Anatomical Context for Microvascular Complications of Diabetes 5

MalaCards organs/tissues related to Microvascular Complications of Diabetes 5:

38
Eye, Retina, Bone
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Microvascular Complications of Diabetes 5:
# Tissue Anatomical CompartmentCell Relevance
1 Eye Outer Nuclear Layer Mature L Cone Cells Potential therapeutic candidate, affected by disease
2 Eye Outer Nuclear Layer Mature M Cone Cells Potential therapeutic candidate, affected by disease
3 Eye Inner Nuclear Layer Mature Muller Glia Cells Affected by disease
4 Eye Outer Nuclear Layer Mature Rod Cells Potential therapeutic candidate, affected by disease
5 Eye Outer Nuclear Layer Mature S Cone Cells Potential therapeutic candidate, affected by disease

Publications for Microvascular Complications of Diabetes 5

Articles related to Microvascular Complications of Diabetes 5:

(show top 50) (show all 1754)
# Title Authors Year
1
Genome-wide mRNA analysis reveals a TUBD1 isoform profile as a potential biomarker for diabetic retinopathy development. ( 28137601 )
2017
2
LOW SERUM BRAIN-DERIVED NEUROTROPHIC FACTOR BUT NOT BRAIN-DERIVED NEUROTROPHIC FACTOR GENE VAL66MET POLYMORPHISM IS ASSOCIATED WITH DIABETIC RETINOPATHY IN CHINESE TYPE 2 DIABETIC PATIENTS. ( 27355244 )
2017
3
The expression of the Slit-Robo signal in the retina of diabetic rats and the vitreous or fibrovascular retinal membranes of patients with proliferative diabetic retinopathy. ( 28973045 )
2017
4
MicroRNA-200b Expression in the Vitreous Humor of Patients with Proliferative Diabetic Retinopathy. ( 28571008 )
2017
5
Serous retinal detachment after panretinal photocoagulation for proliferative diabetic retinopathy: a case report. ( 28923115 )
2017
6
Pathogenic Role of microRNA-21 in Diabetic Retinopathy Through Downregulation of PPARI+. ( 28270521 )
2017
7
Meta-Analysis on the Association of ALDH2 Polymorphisms and Type 2 Diabetic Mellitus, Diabetic Retinopathy. ( 28208752 )
2017
8
Association of IL-6 Gene (-174 and -572 G/C) Polymorphisms with Proliferative Diabetic Retinopathy of Type 2 Diabetes in a Chinese Population. ( 28651253 )
2017
9
Downregulated Brain-Derived Neurotrophic Factor-Induced Oxidative Stress in the Pathophysiology of Diabetic Retinopathy. ( 27913110 )
2017
10
Extracellular matrix metalloproteinase inducer (EMMPRIN) is a potential biomarker of angiogenesis in proliferative diabetic retinopathy. ( 27860331 )
2017
11
ANRIL: A Regulator of VEGF in Diabetic Retinopathy. ( 28122089 )
2017
12
Neovascular glaucoma after vitrectomy in patients with proliferative diabetic retinopathy. ( 28272234 )
2017
13
Idiopathic macular telangiectasis type 2 and co-existent diabetic retinopathy. ( 29299346 )
2017
14
Association analysis of PPARI^ (p.Pro12Ala) polymorphism with type 2 diabetic retinopathy in patients from north India. ( 27427939 )
2017
15
Is leukostasis a crucial step or epiphenomenon in the pathogenesis of diabetic retinopathy? ( 28724696 )
2017
16
Circumpapillary retinal nerve fiber layer thickness, anterior lamina cribrosa depth, and lamina cribrosa thickness in neovascular glaucoma secondary to proliferative diabetic retinopathy: a cross-sectional study. ( 28446148 )
2017
17
Endothelial STAT3 Activation Increases Vascular Leakage Through Downregulating Tight Junction Proteins: Implications for Diabetic Retinopathy. ( 27580405 )
2017
18
The A445C Variant in Apelin Receptor and Diabetic Retinopathy in Tunisian Patients. ( 28182349 )
2017
19
Hyperlipidemia-Mediated Increased Advanced Lipoxidation End Products Formation, an Important Factor Associated with Decreased Erythrocyte Glucose-6-Phosphate Dehydrogenase Activity in Mild Nonproliferative Diabetic Retinopathy. ( 27916496 )
2017
20
The Association of a Genetic Variant in SCAF8-CNKSR3 with Diabetic Kidney Disease and Diabetic Retinopathy in a Chinese Population. ( 28401168 )
2017
21
Transthyretin Exerts Pro-Apoptotic Effects in Human Retinal Microvascular Endothelial Cells Through a GRP78-Dependent Pathway in Diabetic Retinopathy. ( 28950253 )
2017
22
Plasma Kallikrein Inhibitors for the Treatment of Retinal Vascular Permeability Associated with Diabetic Retinopathy and Diabetic Macular Edema. ( 28835783 )
2017
23
Histone HIST1H1C/H1.2 regulates autophagy in the development of diabetic retinopathy. ( 28409999 )
2017
24
CTRP3 is a novel biomarker for diabetic retinopathy and inhibits HGHL-induced VCAM-1 expression in an AMPK-dependent manner. ( 28632765 )
2017
25
Effects of miRNA-200b on the development of diabetic retinopathy by targeting VEGFA gene. ( 28122882 )
2017
26
RELATIONSHIP BETWEEN OBSTRUCTIVE SLEEP APNEA AND THE PRESENCE AND SEVERITY OF DIABETIC RETINOPATHY. ( 28937527 )
2017
27
Epigenetic regulation of redox signaling in diabetic retinopathy: Role of Nrf2. ( 28012783 )
2017
28
A case of pseudoxanthoma elasticum with proliferative diabetic retinopathy. ( 28978321 )
2017
29
Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy. ( 28061854 )
2017
30
Truncated netrin-1 contributes to pathological vascular permeability in diabetic retinopathy. ( 27400127 )
2016
31
Association between the Angiotensin-Converting Enzyme (ACE) Genetic Polymorphism and Diabetic Retinopathy-A Meta-Analysis Comprising 10,168 Subjects. ( 27854313 )
2016
32
Association of reduced Connexin 43 expression with retinal vascular lesions in human diabetic retinopathy. ( 26738943 )
2016
33
Lipoprotein(a) predicts the development of diabetic retinopathy in people with type 2 diabetes mellitus. ( 27055974 )
2016
34
Angiogenic microRNAs Linked to Incidence and Progression of Diabetic Retinopathy in Type 1 Diabetes. ( 26395742 )
2016
35
Type 2 diabetic patients with diabetic retinopathy and concomitant microalbuminuria showed typical diabetic glomerulosclerosis and progressive renal dysfunction. ( 27138869 )
2016
36
Serum and Vitreous Pentraxin 3 Concentrations in Patients with Diabetic Retinopathy. ( 26836044 )
2016
37
Association of Complement C5 Gene Polymorphisms with Proliferative Diabetic Retinopathy of Type 2 Diabetes in a Chinese Han Population. ( 26934706 )
2016
38
Reduced serum level of leukocyte cell-derived chemotaxin 2 is associated with the presence of diabetic retinopathy. ( 27816666 )
2016
39
Diabetic Retinopathy and Diabetic Macular Edema. ( 26501152 )
2016
40
Serum fibroblast growth factor 21 concentrations in type 2 diabetic retinopathy patients. ( 27106505 )
2016
41
Low plasma levels of brain derived neurotrophic factor are potential risk factors for diabetic retinopathy in Chinese type 2 diabetic patients. ( 26493466 )
2016
42
Myopia is inversely associated with the prevalence of diabetic retinopathy in the South Korean Population. ( 27640007 )
2016
43
The Association between VDR Gene Polymorphisms and Diabetic Retinopathy Susceptibility: A Systematic Review and Meta-Analysis. ( 27891515 )
2016
44
Lower Hemoglobin Concentration Is Associated with Retinal Ischemia and the Severity of Diabetic Retinopathy in Type 2 Diabetes. ( 27200379 )
2016
45
Association of genetic variants in the receptor for advanced glycation end products gene with diabetic retinopathy: A meta-analysis. ( 27684793 )
2016
46
Irisin modulates the association of interleukin-17A with the presence of non-proliferative diabetic retinopathy in patients with type 2 diabetes. ( 26940815 )
2016
47
Th17 cell frequency and IL-17A concentrations in peripheral blood mononuclear cells and vitreous fluid from patients with diabetic retinopathy. ( 27885039 )
2016
48
High glucose-induced hyperosmolarity contributes to COX-2 expression and angiogenesis: implications for diabetic retinopathy. ( 26822858 )
2016
49
Gene-gene interaction of erythropoietin gene polymorphisms and diabetic retinopathy in Chinese Han. ( 27190272 )
2016
50
HIGH MYOPIA AND DIABETIC RETINOPATHY: A Contralateral Eye Study in Diabetic Patients With High Myopic Anisometropia. ( 27749693 )
2016

Variations for Microvascular Complications of Diabetes 5

ClinVar genetic disease variations for Microvascular Complications of Diabetes 5:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PON1 NM_000446.6(PON1): c.163T> A (p.Leu55Met) single nucleotide variant risk factor rs854560 GRCh37 Chromosome 7, 94946084: 94946084

Expression for Microvascular Complications of Diabetes 5

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 5.

Pathways for Microvascular Complications of Diabetes 5

Pathways related to Microvascular Complications of Diabetes 5 according to KEGG:

36
# Name Kegg Source Accession
1 AGE-RAGE signaling pathway in diabetic complications hsa04933
2 HIF-1 signaling pathway hsa04066
3 Renin-angiotensin system hsa04614

Pathways related to Microvascular Complications of Diabetes 5 according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.68 ANGPT2 FLT1 INS KDR NOS3 PRKCB
2
Show member pathways
13.56 ANGPT2 FGF2 FLT1 ICAM1 IGF1 INS
3
Show member pathways
13.43 ANGPT2 FGF2 FLT1 IGF1 KDR NOS3
4
Show member pathways
13.33 ALB ANGPT2 IGF1 NOS3 PRKCB SERPINE1
5
Show member pathways
13.31 ANGPT2 FGF2 FLT1 IGF1 KDR PRKCB
6
Show member pathways
13.29 FGF2 FLT1 IGF1 KDR NOS3 PRKCB
7
Show member pathways
13.06 FGF2 IGF1 INS KDR PRKCB VEGFA
8
Show member pathways
13.02 ACE FGF2 FLT1 IGF1 INS KDR
9
Show member pathways
12.91 ANGPT2 FGF2 FLT1 IGF1 INS KDR
10
Show member pathways
12.76 FGF2 ICAM1 KDR SERPINE1 VCAM1
11
Show member pathways
12.71 FGF2 FLT1 IGF1 KDR PRKCB
12 12.68 ANGPT2 FGF2 FLT1 IGF1 INS KDR
13
Show member pathways
12.66 ICAM1 KDR NOS3 PRKCB VCAM1 VEGFA
14
Show member pathways
12.62 ANGPT2 FGF2 FLT1 IGF1 INS KDR
15
Show member pathways
12.59 ANGPT2 FGF2 ICAM1 PRKCB VEGFA
16
Show member pathways
12.52 FLT1 IGF1 INS KDR PRKCB
17
Show member pathways
12.44 FLT1 KDR NOS3 PRKCB
18
Show member pathways
12.39 FGF2 FLT1 KDR VEGFA
19
Show member pathways
12.36 FLT1 KDR NOS3 PRKCB VEGFA
20
Show member pathways
12.36 ICAM1 KDR NOS3 PRKCB VCAM1 VEGFA
21
Show member pathways
12.34 ALB ICAM1 INS SERPINE1
22 12.31 FGF2 IGF1 KDR PRKCB VEGFA
23
Show member pathways
12.18 FGF2 FLT1 KDR NOS3 PRKCB VEGFA
24 12.13 ANGPT2 FGF2 FLT1 KDR TEK
25 12.09 ICAM1 KDR NOS3 VCAM1 VEGFA
26 12 FGF2 ICAM1 VCAM1 VEGFA
27 11.92 ALB FGF2 IGF1 INS KDR VCAM1
28 11.91 FGF2 IGF1 INS VCAM1
29
Show member pathways
11.89 FLT1 KDR NOS3 VEGFA
30 11.87 FLT1 ICAM1 TEK VEGFA
31
Show member pathways
11.83 FLT1 KDR NOS3 PRKCB
32 11.83 ANGPT2 FGF2 FLT1 KDR NOS3 TEK
33 11.78 FGF2 IGF1 VEGFA
34 11.7 AGER INS NOS3 PRKCB
35 11.7 AGER ICAM1 NOS3 PRKCB SERPINE1 VCAM1
36 11.69 FGF2 IGF1 VEGFA
37
Show member pathways
11.67 ICAM1 VCAM1 VEGFA
38 11.58 FGF2 IGF1 INS KDR
39 11.55 FGF2 KDR VEGFA
40 11.52 FGF2 KDR VEGFA
41 11.51 ICAM1 NOS3 VCAM1
42 11.51 FGF2 IGF1 INS VEGFA
43
Show member pathways
11.47 INS KDR VEGFA
44 11.43 FGF2 FLT1 KDR VEGFA
45 11.41 IGF1 INS PRKCB
46 11.4 ANGPT2 SERPINE1 VEGFA
47 11.37 ICAM1 PRKCB VCAM1
48 11.31 FLT1 KDR SERPINE1 VEGFA
49 11.28 ANGPT2 FLT1 IGF1 INS NOS3 PRKCB
50 11.22 FGF2 FLT1 VEGFA

GO Terms for Microvascular Complications of Diabetes 5

Cellular components related to Microvascular Complications of Diabetes 5 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 ACE AGER ALB ANGPT2 FGF2 FLT1
2 cell surface GO:0009986 9.73 AGER AOC3 ICAM1 TEK VCAM1 VEGFA
3 microvillus GO:0005902 9.54 AOC3 TEK VCAM1
4 extracellular space GO:0005615 9.47 ACE AKR1B1 ALB ANGPT2 FGF2 FLT1
5 platelet alpha granule lumen GO:0031093 9.46 ALB IGF1 SERPINE1 VEGFA
6 plasma membrane GO:0005886 10.13 ACE AGER ANGPT2 AOC3 FLT1 ICAM1

Biological processes related to Microvascular Complications of Diabetes 5 according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 peptidyl-tyrosine phosphorylation GO:0018108 9.95 FGF2 FLT1 KDR TEK
2 positive regulation of protein phosphorylation GO:0001934 9.94 AGER KDR TEK VEGFA
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.92 AGER ICAM1 INS PRKCB
4 extracellular matrix organization GO:0030198 9.92 FGF2 ICAM1 KDR SERPINE1 VCAM1
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 AGER FGF2 ICAM1 KDR TEK
6 positive regulation of cell migration GO:0030335 9.89 FLT1 IGF1 INS KDR VEGFA
7 platelet degranulation GO:0002576 9.88 ALB IGF1 SERPINE1 VEGFA
8 positive regulation of MAPK cascade GO:0043410 9.86 FLT1 IGF1 INS KDR
9 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.84 FLT1 KDR VEGFA
10 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.84 ICAM1 IGF1 INS VEGFA
11 positive regulation of MAP kinase activity GO:0043406 9.83 FGF2 FLT1 VEGFA
12 positive regulation of endothelial cell migration GO:0010595 9.81 KDR TEK VEGFA
13 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.78 ICAM1 NOS3 SERPINE1
14 positive regulation of endothelial cell proliferation GO:0001938 9.78 FGF2 KDR TEK VEGFA
15 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.74 FGF2 FLT1 TEK
16 positive regulation of focal adhesion assembly GO:0051894 9.72 KDR TEK VEGFA
17 positive regulation of blood vessel endothelial cell migration GO:0043536 9.71 FGF2 KDR NOS3 VEGFA
18 response to hypoxia GO:0001666 9.7 AGER ANGPT2 ICAM1 PRKCB TEK VCAM1
19 negative regulation of wound healing GO:0061045 9.68 FGF2 SERPINE1
20 induction of positive chemotaxis GO:0050930 9.68 AGER VEGFA
21 negative regulation of calcium ion transport GO:0051926 9.68 ICAM1 NOS3
22 positive regulation of positive chemotaxis GO:0050927 9.67 KDR VEGFA
23 negative regulation of endothelial cell apoptotic process GO:2000352 9.67 ICAM1 KDR SERPINE1 TEK
24 positive regulation of phospholipase C activity GO:0010863 9.66 FGF2 FLT1
25 amine metabolic process GO:0009308 9.66 AOC3 VCAM1
26 vascular endothelial growth factor signaling pathway GO:0038084 9.65 FLT1 KDR
27 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.65 FLT1 IGF1 INS KDR TEK
28 membrane to membrane docking GO:0022614 9.63 ICAM1 VCAM1
29 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.63 ACE VEGFA
30 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.63 FLT1 PRKCB VEGFA
31 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.62 KDR VEGFA
32 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.62 FLT1 KDR VCAM1 VEGFA
33 glomerulus vasculature development GO:0072012 9.61 ANGPT2 TEK
34 cell migration involved in sprouting angiogenesis GO:0002042 9.61 FGF2 KDR VEGFA
35 Tie signaling pathway GO:0048014 9.58 ANGPT2 TEK
36 angiogenesis GO:0001525 9.56 ANGPT2 FGF2 FLT1 KDR NOS3 SERPINE1
37 positive regulation of angiogenesis GO:0045766 9.28 ANGPT2 FGF2 FLT1 KDR NOS3 PRKCB
38 negative regulation of apoptotic process GO:0043066 10.08 AKR1B1 ALB IGF1 KDR TEK VEGFA
39 regulation of receptor activity GO:0010469 10.07 FGF2 IGF1 INS SERPINE1 VEGFA
40 positive regulation of cell proliferation GO:0008284 10.07 FGF2 FLT1 IGF1 INS KDR VEGFA

Molecular functions related to Microvascular Complications of Diabetes 5 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.5 FLT1 KDR TEK
2 protein tyrosine kinase activity GO:0004713 9.46 FGF2 FLT1 KDR TEK
3 vascular endothelial growth factor-activated receptor activity GO:0005021 9.37 FLT1 KDR
4 primary amine oxidase activity GO:0008131 9.26 AOC3 VCAM1
5 growth factor binding GO:0019838 9.13 FLT1 KDR TEK
6 integrin binding GO:0005178 8.92 ICAM1 IGF1 KDR VCAM1

Sources for Microvascular Complications of Diabetes 5

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....